Large Drop in HIV Diagnoses in London gay men 

  Four sexual health clinics serving large numbers of gay men in London have reported that they diagnosed far fewer gay men with HIV during 2016 than they did during 2015.  Many doctors believe that the use of pre-exposure prophylaxis (PrEP) is part of the explanation for these reductions. Such large drops in new diagnoses are […]

Tests of online PrEP purchases find no fakes

PrEP is a course of HIV drugs taken by HIV negative people before sex to reduce the chance of getting HIV. Results in trials have been very successful, with PrEP significantly lowering the risk of becoming HIV positive and without major side effects. The medication used for PrEP is a tablet called Truvada, which contains tenofovir and emtricitabine […]

Legal Challenge to the NHS on PrEP

Pre-Exposure Prophylaxis (PrEP) involves HIV negative people taking an antiretroviral drug to avoid getting HIV. Multiple studies around the world have shown PrEP to be effective in reducing the risk of contracting HIV. After a lengthy review process, during which all the indications were good, the NHS announced that it would not after all commission PrEP in England. […]

PrEP – More Information on NHS U-turn

Yusef Azad is National AIDS Trust (NAT) Director of Strategy. He was closely involved in the work done over the past few years to see whether or not PrEP would be effective at reducing the number of new HIV cases in the UK in a cost-effective way. He has written a blog about the NHS […]

NHS Will Not Roll Out PrEP Across England

The NHS has just announced it has pulled the plug on its decision-making process on whether to offer PrEP (Pre-exposure Prophylaxis – a HIV prevention drug, proven to be effective in stopping HIV transmission in almost every case if taken properly) on the NHS. This is a real shock. NHS England’s press release is here. Deborah […]

Long-lasting injectable formulation?

An oral combination therapy of two antiretroviral drugs, the non-nucleoside rilpivirine (Edurant, also inEviplera/Complera) and the new integrase inhibitor GSK1265744 (744), was at least as effective as a standard nucleosides-plus-efavirenz triple combination in keeping viral load undetectable in people taking it. This dual combination was a maintenance therapy, meaning that patients did not start on it […]